Advertisement

Epidemiology of infection and current guidelines for infection prevention in cystic fibrosis patients

  • K. Schaffer
    Correspondence
    Tel.: +353 1 2214470; fax: +353 1 2214112.
    Affiliations
    Department of Microbiology, St Vincent's University Hospital and School of Medicine and Medical Science, University College Dublin, Elm Park, Dublin 4, Ireland
    Search for articles by this author
Published:February 20, 2015DOI:https://doi.org/10.1016/j.jhin.2015.02.005

      Summary

      The spectrum of bacterial pathogens encountered in cystic fibrosis (CF) lung disease has expanded over the last decade. In addition to established pathogens, such as Pseudomonas aeruginosa, Burkholderia cepacia complex and Staphylococcus aureus, novel Gram-negative non-fermenter bacteria and non-tuberculous mycobacteria have gained in clinical significance. Air sampling performed in inpatient and outpatient clinics, and analysis of cough aerosols expelled by CF patients provides evidence for potential airborne transmission of CF pathogens. Two outbreaks of ‘Mycobacterium abscessus subsp. massiliense’ have been reported among CF patients, raising the question of airborne transmission of non-tuberculous mycobacteria. In response to newer epidemiological evidence, international infection control guidance documents have changed. Guideline documents agree on the importance of specifications for ventilation when planning new CF inpatient facilities. New CF units should consider providing negative-pressure inpatient and outpatient rooms to diminish the risk of airborne contamination of ward corridors and communal areas. Air exchange rates of inpatient rooms and pulmonary function testing rooms need to be considered and optimized whenever possible. International guidelines disagree as to whether patients should be requested to wear masks in the hospital environment.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hospital Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • LiPuma J.J.
        The changing microbial epidemiology in cystic fibrosis.
        Clin Microbiol Rev. 2010; 23: 299-323
        • UK Cystic Fibrosis Registry
        Annual data report.
        2013
        • Millar F.A.
        • Simmonds N.J.
        • Hodson M.E.
        Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005.
        J Cyst Fibros. 2009; 8: 386-391
        • Cystic Fibrosis Foundation
        National Patient Registry 2012 Annual Data Report to the Center Directors.
        Cystic Fibrosis Foundation, Bethesda, MD2013
      1. Cystic Fibrosis Trust. Press Release, 31 July 2014. http://www.cysticfibrosis.org.uk/media/619571/report-highlights-improvements-in-cystic-fibrosis-care-310714%20.pdf

        • Peeters C.
        • Zlosnik J.E.
        • Spilker T.
        • Hird T.J.
        • LiPuma J.J.
        • Vandamme P.
        Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere.
        Syst Appl Microbiol. 2013; 36: 483-489
        • Shallom S.J.
        • Gardina P.J.
        • Myers T.G.
        • et al.
        New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance.
        J Clin Microbiol. 2013; 51: 2943-2949
        • Leão S.C.
        • Tortoli E.
        • Euzéby J.P.
        • Garcia M.J.
        Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus.
        Int J Syst Evol Microbiol. 2011; 61: 2311-2313
        • Harris K.A.
        • Kenna D.T.D.
        Mycobacterium abscessus infection in cystic fibrosis: molecular typing and clinical outcomes.
        J Med Microbiol. 2014; 63: 1241-1246
        • Tunney M.M.
        • Field T.R.
        • Moriarty T.F.
        • et al.
        Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.
        Am J Respir Crit Care Med. 2008; 177: 995-1001
        • Sibley C.D.
        • Parkins M.D.
        • Rabin H.R.
        • Duan K.
        • Norgaard J.C.
        • Surette M.G.
        A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.
        Proc Natl Acad Sci USA. 2008; 105: 15070-15075
        • Mahenthiralingam E.
        Emerging cystic fibrosis pathogens and the microbiome.
        Paediatr Respir Rev. 2014; : 13-15
        • May J.R.
        • Herrick N.C.
        • Thompson D.
        Bacterial infection in cystic fibrosis.
        Archs Dis Childh. 1972; 47: 908
        • Pedersen S.S.
        • Koch C.
        • Hoiby N.
        • et al.
        An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.
        J Antimicrob Chemother. 1986; 17: 505-516
        • Armstrong D.
        • Bell S.
        • Robinson M.
        • et al.
        Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics.
        J Clin Microbiol. 2003; 41: 2266-2267
        • Scott F.W.
        • Pitt T.L.
        Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales.
        J Med Microbiol. 2004; 53: 609-615
        • Fothergill J.L.
        • Walshaw M.J.
        • Winstanley C.
        Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections.
        Eur Respir J. 2012; 40: 227-238
        • Govan J.R.
        • Brown P.H.
        • Maddison J.
        • et al.
        Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.
        Lancet. 1993; 342: 15-19
        • Biddick R.
        • Spilker T.
        • Martin A.
        • LiPuma J.J.
        Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis.
        FEMS Microbiol Lett. 2003; 228: 57-62
        • Hansen C.R.
        • Pressler T.
        • Ridderberg W.
        • Johansen H.K.
        • Skov M.
        Achromobacter species in cystic fibrosis: cross-infection caused by indirect patient-to-patient contact.
        J Cyst Fibros. 2013; 12: 609-615
        • Jørgensen I.M.
        • Krogh Johansen H.
        • Frederiksen B.
        • et al.
        Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients.
        Pediatric Pulmonology. 2003; 36: 439-446
        • Siegel J.D.
        • Rhinehart E.
        • Jackson M.
        • et al.
        Guideline for isolation precautions: preventing transmission of infectious agents in health care settings.
        Am J Infect Control. 2007; 35: S65-S164
        • Jones A.M.
        • Govan J.R.W.
        • Doherty C.J.
        • et al.
        Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak.
        Thorax. 2003; 58: 525-527
        • Panagea S.
        • Winstanley C.
        • Walshaw M.J.
        • Ledson M.J.
        • Hart C.A.
        Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces.
        J Hosp Infect. 2005; 59: 102-107
        • Wainwright C.E.
        • France M.W.
        • O’Rourke P.
        • et al.
        Cough-generated aerosols of Pseudomonas aeruginosa and other gram-negative bacteria from patients with cystic fibrosis.
        Thorax. 2009; 64: 926-931
        • Knibbs L.D.
        • Johnson G.R.
        • Kidd T.J.
        • et al.
        Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis.
        Thorax. 2014; 69: 740-745
        • Clifton I.J.
        • Fletcher L.A.
        • Beggs C.B.
        • Denton M.
        • Conway S.P.
        • Peckham D.G.
        An aerobiological model of aerosol survival of different strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis.
        J Cystic Fibrosis. 2010; 9: 64-68
        • Aitken M.L.
        • Limaye A.
        • Pottinger P.
        • et al.
        Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center.
        Am J Respir Crit Care Med. 2012; 185: 231-232
        • Bryant J.M.
        • Grogono D.M.
        • Greaves D.
        • et al.
        Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study.
        Lancet. 2013; 381: 1551-1560
        • Saiman L.
        • Siegel J.
        Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.
        Infect Control Hosp Epidemiol. 2003; 24: S6-S52
        • Saiman L.
        • Siegel J.
        • LiPuma J.J.
        • et al.
        Infection prevention and control guideline for cystic fibrosis: 2013.
        Infect Control Hosp Epidemiol. 2014; 35
      2. Anonymous. Anforderungen an die Hygiene bei der medizinischen Versorgung von Patienten mit Cystischer Fibrose (Mukoviszidose). http://www.rki.de/DE/Content/Infekt/Krankenhaushygiene/Kommission/Downloads/Mukoviszidose_AG.pdf?__blob=publicationFile

      3. Cystic Fibrosis Trust, Mycobacterium abscessus Infection Control Working Group. Mycobacterium abscessus. Suggestions for infection prevention and control (Interim guidance – October 2013). https://www.cysticfibrosis.org.uk/media/381091/CC15%20-%20NTM%20guidelinesv2.pdf

        • Zuckerman J.B.
        • Zuaro D.E.
        • Prato B.S.
        • et al.
        Bacterial contamination of cystic fibrosis clinics.
        J Cystic Fibrosis. 2009; 8: 186-192
        • Döring G.
        • Jansen S.
        • Noll H.
        • et al.
        Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward.
        Pediatr Pulmonol. 1996; 21: 90-100
        • Morgan D.J.
        • Rogawski E.
        • Thom K.A.
        • et al.
        Transfer of multidrug-resistant bacteria to healthcare workers’ gloves and gowns after patient contact increases with environmental contamination.
        Crit Care Med. 2012; 40: 1045-1051
        • Zuckerman J.B.
        • Prato B.S.
        • Clock S.
        • et al.
        Characterizing bacterial air contamination during CF outpatient visits.
        Pediatr Pulmonol. 2012; 47: 326
      4. Cystic Fibrosis Canada. Infection prevention and control policy for Cystic Fibrosis Canada hosted events or meetings. http://www.cysticfibrosis.ca/about-us/infection-prevention-and-control/infection-prevention-and-control-for-cystic-fibrosis-canada-hosted-events-or-meetings/

      5. Cystic Fibrosis Trust. Cross-infection policy. Guidance for people with cystic fibrosis at events and meetings. http://www.cysticfibrosis.org.uk/media/214962/cross%20infection%20policy%20(2).pdf

      6. CystiskFibrose Denmark. http://www.cff.dk/behandlingogforskning/cfcentrene/retningslinjerkrydsinfektion.html